J&J's Invega Sustenna To Launch "Soon"; Payers Want Compliance Data
This article was originally published in The Pink Sheet Daily
Executive SummaryWall St. analysts offer differing perspectives on the drug's commercial outlook.
You may also be interested in...
Otsuka and Lundbeck’s newly approved long-acting antipsychotic Abilify Maintena enters a sub-sector of the anti-psychotic market dominated by Johnson & Johnson for the last decade, but the new competitor may be able to gain ground by helping to grow the patient population.